CFIUS Approval for ISSI and Some Dyax
Integrated Silicon Solution (Ticker: ISSI) finally received CFIUS approval so it’s pretty much smooth sailing to the closing now. I was modeling a close by next week, but the company is now guiding for December close pending regulatory approvals from Taiwan and China. These will be rubber stamp approvals at this point. I may just close out my position as there are many attractive merger arb plays out there right now.
Yesterday, I initiated a position in Dyax (Ticker: DYAX) (~5% position) at
$35.57. This company is being acquired by Shire for $37.30 in cash plus a $4.00
CVR. There is a wide spread, which can probably be attributed to (1) a
potential material adverse event for a drug still in development, (2) potential
acquisition of the acquirer (Shire) and (3) anti-trust concerns. The Street is
probably most concerned about anti-trust. With all of these factors, you
get a merger arb play with added risks. I have to size this one appropriately
given all the potential risks, but I can see myself going to a 10% position at
some point.
posted by Money Turtle @ 8:40 AM
1 comments
1 Comments:
It does seemed like Shire is taking over a big chunk of the HAE treatment market with the purchase of Dyax. FDA may take a hard look at the deal. I would hold off investing in the arb trade until 1-2 months later to get a clearer view on the regulatory issues. The $4 CVR is tasty I think the chances are greater than 50%.
Post a Comment
<< Home